Vitiligo News

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

VYN201 showed positive effects on biomarkers of vitiligo in a phase 1b trial, VYNE Therapeutics announced in a press release.

In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more.

CHICAGO — An autologous skin cell suspension device allows for faster, more accessible and efficacious melanocyte-keratinocyte transplant procedures for vitiligo, according to a presentation here.

Patients with vitiligo treated with oral povorcitinib showed significant repigmentation of the face and body, Incyte announced in a press release.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

Patients with vitiligo have a significantly lower risk for all-cause and cause-specific mortality compared with matched controls, according to a study.

Researchers created a comprehensive guide about the pharmacology, efficacy, safety and patient cost options of topical ruxolitinib for the treatment of nonsegmental vitiligo.